DB04981InvestigationalGene Therapies
CG7870 is an oncolytic virus therapy for prostate cancer. It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
- Mechanism
- Curator reviewed
CG7870 is genetically engineered to replicate preferentially in prostate tissue, ignoring healthy cells. In this manner, the virus is able to selectively attack and kill tumorous cells.
- Primary indication
- Intended for the treatment of various forms of cancer.Curator reviewed
- Code names
- CG7870
What you can answer from here — as of October 01, 2026
Which companies are running trials of CG7870, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account